Remo-Zen (Remogliflozin Etabonate) belongs to the class of selective inhibitors of the sodium-glucose transport protein 2, which effectively reduce blood glucose and glycated hemoglobin. It is a modern drug, one of the latest advances in medicine used to treat type 2 diabetes and nonalcoholic fatty hepatosis. Also, Remo-Zen (Remogliflozin Etabonate) has a positive effect on blood pressure and contributes to weight loss in obese patients.
